Hysteroscopy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Hysteroscopy is an endoscopic technique that enables direct visual examination of the uterine cavity using a thin, telescope-like instrument called a hysteroscope. A light source and camera project a magnified image onto a monitor, allowing the surgeon to assess the endometrium, uterine walls, tubal ostia, and cervical canal in real time.

Hysteroscopy is classified as either diagnostic or operative:

• Diagnostic hysteroscopy: Examination of the uterine cavity to identify structural or pathological abnormalities. Uses narrow-calibre hysteroscopes (2.7–3.5 mm outer sheath) that can be performed in an outpatient or office setting without general anaesthesia in the majority of women.
• Operative hysteroscopy: Combines diagnostic evaluation with surgical treatment of identified pathology using working channels for mechanical instruments (scissors, graspers), electrosurgical loops (resectoscope), or energy devices. Typically performed in an operating theatre, often under general or regional anaesthesia, though many procedures are now feasible in the office setting with modern miniaturised equipment.

Hysteroscopy has largely superseded blind curettage (D&C) for investigating abnormal uterine bleeding, as it provides direct visual guidance and substantially superior diagnostic sensitivity. Under direct vision, targeted biopsies can be obtained rather than relying on random endometrial sampling.

The procedure requires distension of the uterine cavity with fluid or gas to separate the uterine walls and provide a clear operative field. Distension media selection is a critical safety consideration discussed in detail below.

Hysteroscopy has both diagnostic and therapeutic applications across a broad range of intrauterine pathologies.

Abnormal Uterine Bleeding (AUB)

The most common indication. Hysteroscopy enables direct visualisation of the endometrium in women with heavy, irregular, intermenstrual, or postmenopausal bleeding. It is superior to transvaginal ultrasound for characterising intracavitary lesions and is the gold-standard investigation for postmenopausal bleeding with a thickened endometrium.

Endometrial Polyps

Polyps are focal overgrowths of endometrial glands and stroma, occurring in up to 25% of women with abnormal bleeding. Under direct hysteroscopic vision, polyps can be resected using mechanical polyp forceps, a hysteroscopic morcellator (e.g., MyoSure, Truclear), or monopolar/bipolar loop — achieving complete removal with histological confirmation. Targeted polypectomy under hysteroscopy is significantly more complete than blind curettage.

Submucosal Fibroids

The European Society of Gynaecological Endoscopy (ESGE) STEPW classification categorises submucosal fibroids by their intracavitary component and intramural extension, guiding surgical complexity:

• Type 0: Entirely intracavitary — simplest to resect
• Type I: Intramural extension less than 50%
• Type II: Intramural extension 50% or more — most complex; may require two-stage procedure

Hysteroscopic myomectomy is the preferred treatment for symptomatic submucosal fibroids, particularly in women wishing to preserve uterine function or fertility.

Intrauterine Adhesions (Asherman Syndrome)

Intrauterine adhesions result from endometrial damage (typically following uterine surgery or infection) and may cause amenorrhoea, hypomenorrhoea, or infertility. Hysteroscopic adhesiolysis — division of adhesions under direct vision using scissors or energy — is the treatment of choice, with subsequent oestrogen therapy to promote endometrial regeneration.

Uterine Septum

A uterine septum (congenital Mullerian anomaly) is associated with recurrent miscarriage and preterm birth. Hysteroscopic metroplasty (transcervical resection of the septum) is the gold-standard minimally invasive treatment, performed under laparoscopic guidance to prevent uterine perforation.

Other Indications

• Assessment and removal of a lost or embedded intrauterine device (IUD)
• Targeted endometrial biopsy for suspected hyperplasia or cancer
• Removal of retained products of conception
• Tubal cannulation for proximal tubal obstruction

Hysteroscopy is generally well-tolerated and can be offered to most women with appropriate indications. Pre-procedure assessment helps optimise patient experience and procedural safety.

Who Is Suitable?

• Premenopausal or postmenopausal women with abnormal uterine bleeding or suspected intrauterine pathology
• Women with unexplained infertility or recurrent miscarriage where uterine cavity assessment is indicated
• Women requiring operative intervention for polyps, fibroids, adhesions, or septal abnormalities

Contraindications

• Pregnancy: Absolute contraindication (except for specific obstetric indications)
• Active genital tract infection (PID, cervicitis): Procedure deferred until infection treated; antibiotic prophylaxis may be considered
• Known cervical or uterine malignancy: Diagnostic hysteroscopy may be performed but operative procedures require multidisciplinary oncological review
• Recent uterine perforation: Relative contraindication; timing of repeat hysteroscopy individualised

Pre-procedure Preparation

• Timing: Ideally in the follicular phase (days 6–12 of cycle) for premenopausal women — the endometrium is thinner, providing better visualisation
• Cervical ripening: Misoprostol (vaginal or sublingual) may be used pre-operatively to facilitate cervical dilation, particularly in nulliparous women or those with prior cervical surgery
• Anaesthesia planning: Office procedures typically use paracervical block with or without intrauterine local anaesthetic; theatre procedures may use sedation, spinal, or general anaesthesia
• Patient counselling regarding discomfort: Women should be advised of menstrual-type cramping during the procedure, particularly at cervical dilation

Successful hysteroscopy requires adequate uterine cavity distension, appropriate equipment selection, and safe management of distension media.

Distension Media

Selection of distension medium is determined primarily by the energy modality used for operative procedures:

• Normal saline (0.9%): The preferred medium for diagnostic hysteroscopy and operative procedures using bipolar electrosurgery or mechanical instruments. It is physiologically compatible with body fluids and does not cause electrolyte disturbance even if absorbed in significant volumes. The principal safety parameter is fluid deficit monitoring — absorption of greater than 2,500 mL should prompt termination of the procedure.
• Glycine 1.5%: A hypotonic, electrolyte-free solution required for monopolar electrosurgery (resectoscope loops). Risk of dilutional hyponatraemia and glycine toxicity (visual disturbance, confusion) if excessive absorption occurs. Maximum safe fluid deficit is 1,000 mL (reduced to 750 mL in women with cardiovascular disease). Mandatory fluid deficit monitoring by the circulating nurse throughout the procedure. Glycine use is declining in favour of bipolar systems using normal saline.
• Carbon dioxide (CO2): Used exclusively for diagnostic office hysteroscopy; provides excellent clarity without fluid management concerns. Not suitable for operative hysteroscopy due to risk of CO2 embolism with bleeding.

Equipment

• Rigid hysteroscopes: 2.7–4 mm telescopes; outer sheaths 3.5–5 mm (diagnostic) or up to 9 mm (operative with resectoscope)
• Flexible hysteroscopes: Offer improved patient comfort in office settings; lower resolution than rigid scopes
• Hysteroscopic morcellator: Tissue morcellation devices (MyoSure, Truclear, BIGATTI shaver) enable rapid removal of polyps and type 0–I fibroids using normal saline, without risk of the fluid complications associated with electrosurgical resection
• Resectoscope: Working element with monopolar or bipolar loop for electrosurgical resection of fibroids, septa, and ablation

Endometrial Ablation Techniques

Second-generation endometrial ablation devices destroy the endometrium globally without requiring hysteroscopic skill or distension media, and can be performed in the office or theatre:

• NovaSure (radiofrequency ablation): Fan-shaped bipolar gold mesh electrode ablates the entire endometrium in approximately 90 seconds; 70–80% amenorrhoea rate at 12 months
• ThermaChoice (thermal balloon ablation): Heated water-filled balloon achieves ablation over 8 minutes; amenorrhoea rate approximately 15–25% but high rates of significant bleeding reduction
• Microwave endometrial ablation (MEA) and cryoablation: Alternative energy modalities with comparable efficacy data

Post-ablation tubal sterilisation syndrome is an important late complication: cyclical haematometra trapped behind a closed cornual ostium causes cyclical pelvic pain in women who have had concurrent or prior tubal ligation. Management involves cornual resection or hysterectomy.

Hysteroscopy offers major diagnostic and therapeutic advantages over traditional surgical or radiological approaches to intrauterine pathology.

Diagnostic Superiority

Hysteroscopy is significantly more sensitive than transvaginal ultrasound (TVS), saline infusion sonohysterography (SIS), and blind endometrial biopsy for detecting intracavitary lesions. A 2010 meta-analysis demonstrated hysteroscopic sensitivity of 86% and specificity of 99% for endometrial carcinoma — superior to all non-hysteroscopic alternatives. Direct tissue sampling under vision eliminates the sampling errors inherent to blind curettage.

Therapeutic in the Same Sitting

A major advantage of the 'see and treat' office hysteroscopy model is that diagnosis and treatment can occur in a single visit. Endometrial polyps can be removed, IUDs retrieved, and targeted biopsies obtained without a second anaesthetic episode.

Minimally Invasive

Hysteroscopy is performed through the natural cervical os without abdominal incisions, resulting in no visible scarring, minimal post-procedure pain, and same-day discharge in the vast majority of cases. Most women return to normal activities within 24–48 hours.

Fertility Preservation

Unlike hysterectomy, operative hysteroscopy treats intrauterine pathology while preserving the uterus. Hysteroscopic polypectomy, myomectomy, and adhesiolysis may improve fertility outcomes and implantation rates in women undergoing assisted reproduction.

Superior to Blind D&C

Randomised evidence confirms that hysteroscopically directed biopsy is significantly more accurate than conventional dilatation and curettage (D&C) for diagnosing endometrial pathology. Blind D&C fails to sample up to 60% of the uterine cavity and misses focal lesions in a substantial proportion of cases.

Hysteroscopy is a safe procedure; overall complication rates for diagnostic hysteroscopy are approximately 0.3% and for operative hysteroscopy approximately 1–2%. Awareness of potential complications enables prompt recognition and management.

Immediate Procedural Complications

• Uterine perforation: Most common serious complication, occurring in approximately 0.6–1.4% of operative and 0.1% of diagnostic procedures. Identified by sudden loss of distension or instrument passing beyond expected depth. Management depends on vessel involvement: uncomplicated perforation may be managed conservatively with observation; fundal perforation with lateral instrument passage requires laparoscopy to exclude visceral injury.
• Cervical laceration: Typically minor; occurs during tenaculum placement or cervical dilation. Controlled with pressure or haemostatic suture.
• Vasovagal reaction: Bradycardia and hypotension due to cervical manipulation; managed with positional change, atropine if severe. More common in office settings and postmenopausal women.
• Distension media complications: Fluid overload and hyponatraemia (with glycine) are potentially life-threatening. Prevented by strict real-time fluid deficit monitoring; bipolar systems using normal saline carry lower systemic risk.

Post-procedure Complications

• Infection: Endometritis or pelvic inflammatory disease occurs in approximately 0.2–2% of cases. Antibiotic prophylaxis is not universally recommended for diagnostic hysteroscopy but may be considered for operative procedures in women with risk factors.
• Bleeding: Post-operative bleeding is usually minor and self-limiting; significant haemorrhage requiring transfusion is rare (less than 0.5%).
• Intrauterine adhesion formation: A recognised complication following operative procedures, particularly repeat curettage or myomectomy. Post-operative oestrogen therapy and intrauterine balloon placement may reduce adhesion recurrence.

Long-term Considerations

• Post-ablation tubal sterilisation syndrome in women with prior tubal ligation
• Incomplete resection of submucosal fibroids requiring repeat procedure (particularly type II)
• Fluid absorption risk increases with prolonged operative time; procedures should be completed efficiently

Recovery from hysteroscopy is generally rapid, particularly for diagnostic and minor operative procedures.

Immediate Recovery

• Most women are discharged on the same day as the procedure
• Menstrual-type cramping may persist for several hours; regular paracetamol and ibuprofen provide effective analgesia
• Light vaginal spotting or discharge is normal for 1–2 weeks post-procedure
• A urinary catheter is not routinely required

Resuming Normal Activities

• Return to work: Most women can return to office-based work within 24–48 hours for diagnostic procedures; 3–5 days after larger operative procedures
• Avoid penetrative intercourse, tampons, and swimming for 1–2 weeks to reduce infection risk while the cervix reseals
• Heavy lifting restrictions are not typically required following hysteroscopy

Post-operative Symptoms Requiring Review

Women should be advised to seek prompt medical review if they experience:

• Fever above 38°C
• Heavy vaginal bleeding (soaking more than one pad per hour)
• Severe abdominal pain not controlled by standard analgesia
• Offensive vaginal discharge suggesting infection

Follow-up Appointments

A post-procedure appointment (typically 4–6 weeks) is arranged to review histopathology results, assess treatment response, and plan further management if required. Women undergoing hysteroscopic adhesiolysis for Asherman syndrome require repeat hysteroscopy to assess cavity restoration and guide ongoing care. Women treated for endometrial hyperplasia require endometrial surveillance per established protocols.

The cost of hysteroscopy depends on whether the procedure is diagnostic or operative, the setting (office vs theatre), anaesthesia requirements, and geographic location.

Approximate Costs by Setting and Region

• United Kingdom (NHS): Provided free at the point of care for eligible patients; private diagnostic hysteroscopy ranges from £700–£1,500; operative hysteroscopy (polypectomy, myomectomy) from £1,500–£4,000
• United States: Office diagnostic hysteroscopy approximately $500–$1,500; operative hysteroscopy in theatre $2,000–$8,000 or more depending on complexity and facility fees
• India: Diagnostic hysteroscopy approximately £100–£300; operative hysteroscopy £300–£900 at accredited centres
• Thailand / Malaysia: Operative hysteroscopy typically £500–£1,500 at internationally accredited hospitals

Factors Affecting Cost

• Procedure type: Diagnostic examination significantly less costly than operative resection
• Equipment: Hysteroscopic morcellators (MyoSure, Truclear) carry higher disposable equipment costs than conventional resectoscopes
• Anaesthesia: Office procedures with local anaesthesia are considerably less expensive than theatre general anaesthesia
• Complexity: Type II submucosal fibroid resection requiring a two-stage procedure doubles procedural costs
• Histopathology: Laboratory fees for all resected tissue are standard

The trend toward office hysteroscopy ('see and treat') represents a significant cost-saving model compared with traditional theatre-based approaches, without compromise to clinical outcomes for appropriately selected patients.

While hysteroscopy is the gold standard for direct uterine cavity assessment and treatment, alternative diagnostic and therapeutic approaches are available depending on the clinical indication.

Diagnostic Alternatives

• Transvaginal ultrasound (TVS): First-line investigation for AUB and suspected uterine pathology. Accurate for measuring endometrial thickness but less reliable than hysteroscopy for characterising focal intracavitary lesions such as polyps or small fibroids.
• Saline infusion sonohysterography (SIS / SHG): Instillation of saline into the uterine cavity during transvaginal ultrasound improves detection of intracavitary pathology; diagnostic accuracy approaches hysteroscopy for polyps and fibroids, but does not enable simultaneous treatment.
• MRI pelvis: Excellent for characterising myometrial pathology (adenomyosis, fibroid mapping, uterine anomalies) but inferior to hysteroscopy for intracavitary assessment and does not permit tissue sampling.
• Blind endometrial biopsy (Pipelle): Outpatient biopsy sampling approximately 4% of the uterine surface; adequate for global endometrial pathology (diffuse hyperplasia, carcinoma) but misses focal lesions.

Therapeutic Alternatives

• Levonorgestrel IUS (Mirena): For AUB without significant structural pathology — reduces menstrual blood loss by up to 90% and is NICE first-line for heavy menstrual bleeding
• Uterine artery embolisation (UAE): For symptomatic fibroids not suitable for hysteroscopic resection (type II or larger); effective but requires interventional radiology expertise
• Laparoscopic or open myomectomy: For fibroids that cannot be adequately resected hysteroscopically
• Hysterectomy: Definitive treatment when all uterus-sparing options have failed or are inappropriate